2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
3
Lung Neoplasms
3
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Interventions
Irinotecan
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Oxaliplatin
4
Fluorouracil
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
napabucasin
3
Ocoxin
3
Leucovorin
3
pembrolizumab
2
Sorafenib
2
Paclitaxel
2
Nivolumab
2
Drug Therapy
2
Cyclophosphamide
2
Colonoscopy
2
Cetuximab
2
Bupivacaine
2
Aspirin
2
Ascorbic Acid
2
trifluridine tipiracil drug combination
1
trametinib
1
pralsetinib
1
penpulimab
1
ozanimod
1
lutetium Lu 177 dotatate
1
linifanib
1
hetrombopag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Diseases
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA